STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) are approved by FDA for all indications of reference products ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Celltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai ...

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company has been selected and will be included as a constituent of the Hang ...

Celltrion announced on the 24th that it has received product approval from the European Commission (EC) for ACTEMRA ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...

Tocilizumab belongs to a class of drugs called biological disease-modifying antirheumatic drugs or bDMARDs. It blocks receptors for interleukin-6 (IL-6), a signaling protein that tells the immune ...

Rheumatoid arthritis (RA) is a chronic autoimmune disease (one in which the immune system attacks healthy cells) that primarily affects your joints. It is a progressive condition that gets worse over ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.